FDA Nixes Rintatolimod for Chronic Fatigue Syndrome FDA Nixes Rintatolimod for Chronic Fatigue Syndrome
The FDA asked Hemispherx to perform at least 1 more clinical trial, nonclinical studies, and data analyses of Ampligen for chronic fatigue syndrome before reconsidering the New Drug Application. Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news
More News: Chronic Fatigue Syndrome | Clinical Trials | Health | New Drug Applications | Rheumatology | Study